Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Innate initiates phase I study of IPH-4102 in CTCL

Nov. 5, 2015

Launch of managed access program for Unituxin

Nov. 4, 2015

Merck & Co. receives FDA breakthrough therapy designation for Keytruda in colorectal cancer

Nov. 3, 2015

OncoSec Medical starts biomarker study of ImmunoPulse IL-12 in triple-negative breast cancer

Nov. 2, 2015

Igenica Biotherapeutics begins strategic oncology research agreement with MedImmune

Oct. 30, 2015

FDA approves Yervoy for adjuvant treatment of fully resected stage III melanoma

Oct. 29, 2015

KaloBios starts phase I trial of KB-003 in patients with CMML

Oct. 29, 2015

FDA approves Imlygic as first oncolytic viral therapy in U.S.

Oct. 28, 2015

Pembrolizumab superior to docetaxel in overall survival of patients with advanced NSCLC

Oct. 27, 2015

CHMP recommends approval of Imlygic for unresectable melanoma

Oct. 26, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...